We are leading a new era in oncology
Revolutionizing Cancer Care with Precision Therapies
What is Theranostics?
The term Theranostics refers to the combination of a therapeutic and a diagnostic tool in a single agent. In oncology and nuclear medicine, Theranostics involve using the same or similar molecules for both molecular imaging and targeted therapy.
The Science behind RadioNabs®
RadioNabs® are created by the immune system of alpacas
An innovative technology that redefines cancer treatment through precision targeting and advanced molecular science. Our technology utilizes nanoantibodies—a unique type of antibody derived from alpacas—to create highly specific and effective therapies against cancer.
How RadioNab® Works
Combines these advanced nanoantibodies with therapeutic radioisotopes, which are radioactive molecules designed to deliver targeted radiation.
This dual approach of specificity and targeted radiation minimizes side effects often associated with traditional cancer therapies, such as chemotherapy and external beam radiation, while maximizing therapeutic efficacy.
Why Alpacas?
South American camelids.
The Andes Mountains provide the natural habitat for South American camelids, including alpacas. We are privileged to access an alpaca platform in Chile, situated in a region offering ideal geographic and environmental conditions for maintaining healthy, naturally raised alpacas.
The Origins: A Curious Observation in Camelids
The story begins in the early 1990s at the Vrije Universiteit Brussel in Belgium. A group of scientists led by Professor Raymond Hamers was studying the immune systems of camelids—animals like camels, llamas, and alpacas. They made a surprising discovery: camelid blood contained not only conventional antibodies (which consist of two heavy and two light chains), but also a unique type of antibody composed of only heavy chains.
Even more remarkably, the antigen-binding portion of these heavy-chain-only antibodies—just a single domain, later named the VHH domain—could function independently and still bind to targets with high affinity and specificity. This small, stable fragment became known as a nanoantibody.
Why Are Nanoantibodies Special?
Nanoantibodies are typically about one-tenth the size of a conventional antibody, but they pack a powerful punch:
- Stability: They remain functional in extreme conditions like heat, pH changes, and proteolytic environments.
- Solubility: Their small size allows better tissue penetration and even the possibility of delivery via inhalation.
- Simplicity: They can be produced in bacteria, yeast, or even algae, reducing manufacturing costs significantly.
- Targeting Power: Nanoantibodies can access hidden or concave epitopes that traditional antibodies cannot reach—making them excellent tools for diagnostics, imaging, and therapy.
Nanoantibodies Today—and Tomorrow Today, nanoantibodies are used in:
- Immunotherapy (e.g., targeting tumor antigens)
- Diagnostic imaging (e.g., PET scans with radiolabeled nanoantibodies)
- Antiviral therapies (including neutralizing SARS-CoV-2)
- Targeted drug delivery
- Aquaculture and veterinary medicine
The simplicity of nanobody discovery—from immunizing an alpaca to building a phage display library and screening against specific targets—makes them ideal for rapid response in new disease areas or novel therapeutic
What makes Berking special?
Our founders have developed a unique technology that optimizes immunization and enables the identification of ultra-high-affinity nanoantibodies. This technology has been validated through multiple publications in prestigious scientific journals. Berking Theranostics holds an exclusive license to expand this platform for cancer therapeutics—now known as RadioNabs®.
About Our Work
What Are Nanoantibodies?
Nanobody®, a cutting-edge SANOFI trademark.
These single-domain antibodies, known for their small size and robust stability, unlock new potentials in targeted therapy. With excellent tumor penetration and rapid clearance from non-target areas, they offer a unique opportunity to develop next-generation, targeted cancer treatments..
Step into the future of precision medicine with RadioNab®.
Our solutions
Solid tumours
Triple-Negative Breast Cancer
Hormone-Sensitive Breast Cancer
Prostate Cancer
We are developing RadioNabs® for mutiple indications.
We develop antitumoral diagnostic and therapeutic tools. Our unique approach leverages the incredible potential of alpaca-derived nanoantibodies to target and treat solid tumors more effectively and precisely.
With the support of our partners and guidance from our incredible mentors, we are excited to explore new avenues for treating solid tumors. Our goal is to bring innovative solutions to the forefront of cancer treatment and ultimately improve patient outcomes.
Let's share our challenges